Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:30 PM
Ignite Modification Date:
2025-12-24 @ 11:30 PM
NCT ID:
NCT04541056
Eligibility Criteria:
The Norwegian Cancer Registry will identify participants based on the following criteria:
* Acute Lymphoblastic Leukaemia (ALL), Acute Myelogen Leukemia (AML), non Hodgkins Lymphoma diagnosed between 1980 - 2017
* Age when diagnosed \<18 år (0-17years)
* Age at survey 18-40 years
* Born between 1980 - 2004
* Minimum five years (≥5) post ALL, AML, NHL diagnosis
* ALL, AML, NHL treatment at Oslo University Hospital and St. Olavs Hospital
Inclusion Criteria
Screening/baseline:
* Written informed consent
* ≥5 years from diagnosis
* Age 18-40
* Without cancer recurrence the last five years
* Understand and speak Norwegian
Additional inclusion criteria for the intervention:
* Experiencing executive dysfunction as determined by a semi-structured interview
* Cognitive capacity to engage with the training, and General Ability Index (GAI) Score ≥70 measured by Wechsler Intelligence Scale for Adults (WAIS-IV)
Exclusion Criteria:
* Cancer recurrence within the last five years
* A history of premorbid Central Nervous System (CNS) injury or disease (e.g., Traumatic brain injury with noticeable cognitive changes, loss of consciousness or injury discovered on CT or MR)
* Pre-existing attention deficit hyperactivity disorder (ADHD)
* Motor or sensory damage impeding study participation
* A major psychiatric disease and/or ongoing substance abuse impeding study participation
* Present suicidal ideation
* Down syndrome
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
40 Years
Study:
NCT04541056
Study Brief:
Protocol Section:
NCT04541056